Disease/Infection News

RSS

Tel Aviv University researchers discover a protein that kills bacteria

In the arms race between bacteria and modern medicine, bacteria have gained an edge. In recent decades, bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat. Scientists worry that a particularly virulent and deadly "superbug" could one day join the ranks of existing untreatable bacteria, causing a public health catastrophe comparable with the Black Death.

3 Dec 2013

Researchers discover why parasite that causes deadliest form of malaria only infects humans

Researchers have discovered why the parasite that causes the deadliest form of malaria only infects humans.

3 Dec 2013

Tips to protect yourself from getting sick during cold and flu season

As you travel to visit friends and family this holiday season, don't leave home without the hand sanitizer. During cold and flu season, that's one of three things you can do to protect yourself from getting sick you're on the go.

3 Dec 2013

U.S. Administration to provide $5 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria

In an address recognizing World AIDS Day, President Barack Obama announced today that the U.S. Administration will commit up to $5 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria over the next three years. Specifically, he said the United States will contribute $1 for every $2 provided by other donors worldwide through 2016, up to $5 billion.

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

Investigators use new technique to identify pathogens faster, directly from clinical samples

A team of Danish investigators has shown how to identify pathogens faster, directly from clinical samples. The research, published online ahead of print in the Journal of Clinical Microbiology appears in the journal's January 2014 issue.

2 Dec 2013

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

2 Dec 2013

GFF launches education campaign to stop violence against women in DRC, prevent HIV/AIDS in military

The Gertler Family Foundation, in partnership with the Armed Forces of the Democratic Republic of the Congo, marked World AIDS Day by launching an aggressive new education campaign to stop violence against women in the DRC and prevent the spread of HIV/AIDS in the military.

2 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

World AIDS Day: (RED) invites the world to join in fight against AIDS

World AIDS Day marks a time to celebrate how far we've come in the fight to end AIDS, as well as a time to shine a global spotlight on the monumental, historical opportunity now upon us to deliver the world's first AIDS Free Generation in over 30 years.

30 Nov 2013

ATGC, AHF to host dedication ceremony for new AIDS services facility in Cleveland

In conjunction with the 25th observation of World AIDS Day this weekend (observed each year on December 1st), AIDS Taskforce of Greater Cleveland and AIDS Healthcare Foundation, two respected organizations that combined forces in a new partnership to improve delivery of lifesaving HIV/AIDS care and services in Ohio earlier this year, are hosting a candlelight vigil and building dedication ceremony of its new all-in-one AIDS services facility in Cleveland.

30 Nov 2013

UC San Diego biophysicists discover how antibiotic resistance allows bacteria to multiply

Using quantitative models of bacterial growth, a team of UC San Diego biophysicists has discovered the bizarre way by which antibiotic resistance allows bacteria to multiply in the presence of antibiotics, a growing health problem in hospitals and nursing homes across the United States.

30 Nov 2013

Food safety tips for people with HIV/AIDS

December 1, 2013 is World AIDS Day and while the connection between HIV/AIDS (Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) and food safety may not seem obvious, it's actually crucial.

30 Nov 2013

New methods reduce mother-to-child transmission of HIV from 23.9% to 2.4% in Gipuzkoa

Miren Apilánez, researcher in the Department of Paediatrics of the UPV/EHU-University of the Basque Country, has studied the evolution that took place between 1984 and 2011 in paediatric HIV infection in Gipuzkoa. The development of methods to diagnose the disease coupled with increasingly more effective treatments have made it possible to reduce mother-to-child transmission (vertical transmission) from 23.9% to 2.4%, thus virtually eradicating infection in children.

30 Nov 2013

LifeStyles Condoms partners with AIDS Healthcare Foundation to raise awareness for World AIDS Day

The makers of LifeStyles Condoms, one of the nation's leading condom brands, today announced the launch of the #LetsChangeEverything social media campaign in partnership with the AIDS Healthcare Foundation to raise awareness for World AIDS Day on December 1, 2013.

29 Nov 2013

Maintaining antiretroviral adherence: An ongoing challenge for women with HIV

To mark World AIDS Day (December 1, 2013), Women for Positive Action - a global, multidisciplinary group of experts committed to addressing the specific concerns of women living with HIV - has released a commentary highlighting the challenges faced by women in maintaining adherence to their antiretroviral treatment.

29 Nov 2013

Government of Canada awards $8.76M in funding to develop cure for HIV

In the push for a cure for HIV, the Government of Canada has announced $8.76 million in funding to Université de Montréal and Institut de recherches cliniques de Montréal Professor éric A. Cohen, who will lead an unrivaled group of Canadian investigators and international collaborators with a strong track record of interactive research.

29 Nov 2013

Study brings effective hepatitis C cure closer to reality

Scientists at The Scripps Research Institute have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal unexpected structural features of this protein and should greatly speed efforts to make an effective hepatitis C vaccine.

29 Nov 2013

Scientists design small synthetic molecules capable of blocking AIDS virus replication

A multidisciplinary team of scientists from Spanish universities and research centres, among which is the University of Valencia, has managed to design small synthetic molecules capable of joining to the genetic material of the AIDS virus and blocking its replication.

28 Nov 2013

Disease/Infection News

Tel Aviv University researchers discover a protein that kills bacteria

Researchers discover why parasite that causes deadliest form of malaria only infects humans

Tips to protect yourself from getting sick during cold and flu season

U.S. Administration to provide $5 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria

Newly identified protein could prove promising new drug target for AIDS

Investigators use new technique to identify pathogens faster, directly from clinical samples

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

GFF launches education campaign to stop violence against women in DRC, prevent HIV/AIDS in military

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

World AIDS Day: (RED) invites the world to join in fight against AIDS

ATGC, AHF to host dedication ceremony for new AIDS services facility in Cleveland

UC San Diego biophysicists discover how antibiotic resistance allows bacteria to multiply

Food safety tips for people with HIV/AIDS

New methods reduce mother-to-child transmission of HIV from 23.9% to 2.4% in Gipuzkoa

LifeStyles Condoms partners with AIDS Healthcare Foundation to raise awareness for World AIDS Day

Maintaining antiretroviral adherence: An ongoing challenge for women with HIV

Government of Canada awards $8.76M in funding to develop cure for HIV

Study brings effective hepatitis C cure closer to reality

Scientists design small synthetic molecules capable of blocking AIDS virus replication

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News